Long-Term Visual Outcome in Inferior Posterior Staphyloma and Efficacy of Treatment for Complicated Choroidal Neovascularization





Purpose


To investigate long-term visual outcome in inferior posterior staphyloma (IPS) in each group classified based on macular complications and to examine the treatment effect for eyes with IPS with choroidal neovascularization (CNV).


Design


Prospective clinical cohort study.


Participants


We analyzed 56 eyes of 43 consecutive patients with IPS who were followed for 4 years.


Methods


We classified eligible eyes into 3 groups based on baseline findings: eyes without CNV or retinal exudate (no-exudate group), eyes without CNV and with retinal exudate (exudate group), and eyes with CNV (CNV group). We investigated the best-corrected visual acuity (BCVA) and associated parameters for 4 years.


Results


BCVA declined during 4 years only in the exudate group ( P = .002), whereas it was maintained for 4 years in the no-exudate and CNV groups ( P = .53 and .20, respectively). Baseline BCVA was lower in the CNV group than in the exudate group ( P = .004); however, the 4-year BCVA was not ( P = .84). The 4-year BCVA was associated with baseline BCVA in all groups. Eyes in the CNV group required 9.0 ± 8.7 anti–vascular endothelial growth factor therapy in 4 years.


Conclusions


Better baseline BCVA in eyes with exudative IPS without CNV spontaneously declined in 4 years, whereas worse baseline BCVA in eyes with IPS with CNV did not, probably because of treatment for retinal exudate from CNV. Anti–vascular endothelial growth factor therapy would be effective for long-term maintenance of BCVA in eyes with IPS with CNV, similar to other diseases with CNV.


I nferior posterior staphyloma (IPS) is a subtype of posterior staphyloma proposed by Curtin, who reported that IPS was observed in only 12 of 453 eyes (2.6%) with myopic staphyloma, although the prevalence of IPS has not yet been reported. IPS is often accompanied by tilted disc syndrome, peripapillary crescent, and dysversion of retinal vessels. When the upper-temporal border of the IPS lies across the macula, macular complications, including choroidal neovascularization (CNV, 25%), serous retinal detachment (SRD, 41%), and retinal pigment epithelium (RPE) atrophy (13%), often develop and lead to visual loss. , Especially in eyes with IPS with CNV, best-corrected visual acuity (BCVA) has been reported to be worse than in eyes with IPS with other macular complications. However, there is no longitudinal study to demonstrate long-term visual outcome in eyes with IPS.


The efficacy of intravitreal anti–vascular endothelial growth factor (anti-VEGF) agent injections and photodynamic therapy (PDT) for various exudative macular diseases with CNV, including neovascular age-related macular degeneration (AMD), polypoidal choroidal vasculopathy, and myopic CNV, has been reported in long-term observation. A previous multicenter study with >1-year observation period demonstrated that visual prognosis of SRD in eyes without CNV and with tilted disc syndrome, which is often accompanied by IPS, was better when SRD resolved but not influenced by anti-VEGF therapy or PDT. The long-term effect of treatment for CNV with IPS eyes has not been identified.


In the present study, we classified eyes with IPS into 3 groups on the basis of macular complications, as previously reported, and examined long-term visual outcome in eyes with IPS in each group and the effect of therapy for eyes with IPS with CNV.


METHODS


The ethics committee of Kyoto University Graduate School of Medicine (Kyoto, Japan) approved this prospective clinical cohort study. All study protocols adhered to the tenets of the Declaration of Helsinki. We explained the nature of the study, and the possible risks and benefits of participation were explained to all study candidates, who agreed to participate after providing written informed consent.


Participants


This study included treatment-naïve eyes affected by IPS in consecutive patients who visited Kyoto University Hospital between January 2008 and May 2016. All eyes underwent a comprehensive ophthalmologic examination, including autorefractometry (ARK1; Nidek, Gamagori, Japan), BCVA measurements with a 5-m Landolt chart, measurement of intraocular pressure, indirect ophthalmoscopy, slit-lamp biomicroscopy with contact lens, axial length (AL) measurement using partial coherence interferometry (IOLMaster; Carl Zeiss Meditec, Dublin, California, USA), color fundus photography (TRC-NW8F; Topcon Corp, Tokyo, Japan), optical coherence tomography (OCT, Spectralis HRA+OCT, Heidelberg Engineering, Heidelberg, Germany; RS-3000 Advance, Nidek; or DRI OCT-1, Topcon), fundus fluorescein angiography, and indocyanine green angiography (Heidelberg Retina Angiography 2; Heidelberg Engineering).


Retinal specialists diagnosed IPS on the basis of fundus photography, dilated binocular indirect ophthalmoscopy, and slit-lamp biomicroscopy with contact lens. As previously reported, vertical scans of OCT were used to confirm that the border of the inferior staphyloma lay across the macula. The inclusion criterion was IPS, of which the superior edge was lying across the macula, followed for 4 years. The exclusion criteria were as follows: the absence of baseline and 4-year BCVA and OCT image; poor OCT image quality for analysis at baseline; photocoagulation or PDT for eyes without CNV during the observation period; and other baseline macular diseases, including epiretinal membrane, vitreomacular traction syndrome, diabetic retinopathy, and macular hole.


Classification


We classified eligible eyes with IPS into 3 groups on the basis of macular complications at baseline ( Figure 1 ), as previously reported 2 : (1) eyes without CNV or retinal exudate including SRD or retinal pigment epithelial detachment (no-exudate group), (2) eyes without CNV and with retinal exudate (exudate group), and (3) eyes with CNV (CNV group). We carefully determined the presence or absence of CNV on the basis of OCT, fluorescein angiography, and indocyanine green angiography findings. We performed pro re nata (PRN) intravitreal anti-VEGF agent injections (Eylea, Bayer, Basel, Switzerland; Lucentis, Novartis, Basel, Switzerland) in eyes with exudate in the CNV group. When the poor effectiveness of anti-VEGF therapy was confirmed, we performed additional PDT. In the no-exudate and exudate groups, we confirmed CNV development in the 4-year observation period.




Figure 1


Representative vertical-scan optical coherence images used for classification based on macular complication. Eligible eyes with inferior posterior staphyloma were classified into 3 groups based on macular complication at baseline. (Top) No-exudate group. Eyes without choroidal neovascularization (CNV) or retinal exudate of subretinal detachment or retinal pigment epithelial detachment. (Middle) Exudate group. Eyes without CNV and with retinal exudate. (Bottom) CNV group. Eyes with CNV.


Analysis of OCT Images and Color Fundus Photography Images


We measured the central retinal thickness (CRT), central choroidal thickness (CCT), subretinal fluid (SRF) height at the foveal center, and the distance between the upper border of the IPS and fovea (defined as “border-fovea distance”) on a vertical-scan OCT image through the fovea using the built-in software. We defined CRT as the distance between the vitreoretinal surface and the outer surface of the RPE. We defined CCT as the distance between the outer surface of Bruch’s membrane and the chorioscleral interface. We defined SRF height as the distance between the outer surface of the sensory retina and the inner surface of RPE. In addition, we defined the border-fovea distance as the distance between the inner surface of the RPE at the fovea and that at the upper border, which we defined as the thinnest point of the choroid ( Figure 2 ) because previous studies showed that eyes with IPS often have a belt-shaped area with the thinnest choroid being at the superior border of the staphyloma. , Positive values of the border-fovea distance demonstrated that the fovea lies superior to the border. We confirmed tilted disc on the basis of color fundus photography images.




Figure 2


Measurement of the border-fovea distance. We defined the distance between the upper border of the staphyloma and fovea as the border-fovea distance. It was measured as the distance between the inner surface of the retinal pigment epithelium at the fovea (the right arrowhead) and that at the upper border, which was defined as the thinnest point of the choroid (left arrowhead) on a vertical-scan OCT image through the fovea using built-in software.


Statistical Analysis


As applicable, we presented all data as mean ± standard deviation or number of eyes. We converted all BCVA values into the logarithm of the minimum angle of resolution (logMAR) values for statistical analysis. Among the 3 groups, we performed comparison analyses using 1-way analysis of variance and subsequent pairwise comparisons and χ 2 trend test where applicable. Using repeated measures analysis of variance in each group, we analyzed the change in logMAR BCVA values in 4 years (baseline, 6-month, 1-year, 2-year, 3-year, and 4-year BCVA values). Using Spearman’s correlation coefficient, we performed univariate correlation analyses between the 4-year logMAR BCVA and baseline or treatment-associated parameters; and between the 4-year change in logMAR BCVA and those parameters. Multivariate correlation analyses were performed using the 4-year logMAR BCVA or 4-year change in logMAR BCVA as the dependent variable and baseline or treatment-associated parameters with P values <.20 on Spearman’s correlation test as independent variables. We conducted all statistical analyses using SPSS version 27 software (IBM Corp, Armonk, New York, USA).


RESULTS


In the present study, we included 56 eyes of 43 patients (mean age, 64.1 ± 10.5 years; Table 1 ). We classified 25, 21, and 10 eyes into no-exudate, exudate, and CNV groups, respectively. Thus, the prevalence of eyes with retinal exudate was 21 of 46 (46%) eyes without CNV, and that of eyes with CNV was 10 of 56 (18%) eyes with whole IPS. Comparing the 3 groups, significant differences were found in the baseline and 4-year logMAR BCVA ( P < .001 and P = .005, respectively), 4-year change in logMAR BCVA ( P = .01), baseline CRT ( P = .005), 4-year change in CRT ( P = .04), and the prevalence of tilted disc at baseline ( P = .04). Among the 3 groups, the border-fovea distance was not different. In the CNV group, 2 eyes had no retinal exudate at baseline and developed retinal exudate 1 and 3 years after baseline. Taken together, all eyes in the CNV group underwent anti-VEGF therapy (9.0 ± 8.7 injections), and 1 eye underwent not only anti-VEGF therapy but also PDT twice because of the poor effectiveness of anti-VEGF monotherapy. CNV did not develop in 4 years in either the no-exudate group or the exudate group.



Table 1

Comparison of the Studied Parameters Among the 3 Groups
















































































































































































































































Whole Group No-Exudate Group (G1) Exudate Group (G2) CNV Group (G3) P Values Among the 3 Groups P Values of Pairwise Comparisons
G1 vs G2 G1 vs G3 G2 vs G3
Eyes (patient) (n) 56 (43) 25 (25) 21 (17) 10 (9)
Age (y) (range) 64.1 ± 10.5 (42-83) 64.4 ± 11.2 (42-83) 61.3 ± 9.7 (42-77) 69.0 ± 9.6 (48-83) .16
Sex (M/F) (n) 6/37 5/20 2/15 2/7 .21 a
Tilted disc (%) (n) 35 (63) 12 (48) 15 (71) 8 (80) .04 a , * .06 .04 * .31
Axial length (mm) (range) 25.12 ± 1.35 (22.11-28.60) 25.25 ± 1.36 (22.48-28.60) 24.95 ± 1.52 (22.11-28.46) 25.15 ± 0.95 (23.73-26.86) .75
LogMAR BCVA (range)
Baseline 0.19 ± 0.31 0.08 ± 0.23 0.18 ± 0.23 0.53 ± 0.41 <.001 * .41 <.001 * .004 *
4 y 0.20 ± 0.29 0.06 ± 0.19 0.28 ± 0.34 0.35 ± 0.29 .005 * .03 * .03 * .84
Change 0.002 ± 0.26 −0.01 ± 0.22 0.11 ± 0.24 −0.18 ± 0.30 .01 * .22 .17 .009 *
Central retinal thickness (μm)
Baseline 274.3 ± 120.2 219.5 ± 36.9 286.7 ± 97.1 385.0 ± 203.4 .005 * .02 * .07 .35
4 y 215.3 ± 48.5 213.2 ± 39.4 225.1 ± 41.8 200.2 ± 76.7 .40
Change −59.6 ± 127.5 −13.2 ± 28.4 −55.3 ± 100.0 −184.8 ± 227.0 .04 * .17 .09 .24
Central choroidal thickness (μm)
Baseline 127.9 ± 72.1 115.2 ± 75.8 148.9 ± 66.3 115.9 ± 70.9 .25
4 y 114.1 ± 56.8 110.0 ± 57.7 127.9 ± 54.1 95.7 ± 58.9 .30
Change −9.0 ± 104.4 −10.5 ± 31.3 15.4 ± 136.9 −56.8 ± 135.6 .20
Border-fovea distance (μm) (+, the fovea superior to the border)
Baseline 148.3 ± 602.0 183.1 ± 662.2 230.5 ± 511.7 −111.7 ± 607.4 .32
4 y 175.2 ± 620.3 219.4 ± 670.5 274.2 ± 503.9 −143.3 ± 668.7 .19
Change 26.9 ± 115.7 36.3 ± 99.8 43.67 ± 129.9 −31.6 ± 114.1 .21
SRF height at the foveal center (μm) 0 66.0 ± 76.8 27.7 ± 64.8
Anti-VEGF injections in 4 y (n) 0 0 9.0 ± 8.7
Photodynamic therapy in 4 y (n) 0 0 0.2 ± 0.6
CNV development in 4 y (n) 0 0

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Dec 24, 2021 | Posted by in OPHTHALMOLOGY | Comments Off on Long-Term Visual Outcome in Inferior Posterior Staphyloma and Efficacy of Treatment for Complicated Choroidal Neovascularization

Full access? Get Clinical Tree

Get Clinical Tree app for offline access